IDEV

BRIEF-Indevus Pharmaceuticals Q4 results - 11/25 - 07:45 AM ET

IDEV: Conference call regarding Indevus Pharmaceuticals to Announce Fiscal 2008 Financial Results on Tuesday, November 25, 2008 @ 09:00 ET Today [delayed] - 11/25 - 07:23 AM ET

Indevus Pharmaceuticals to Announce Fiscal 2008 Financial Results on Tuesday, November 25, 2008 - 11/18 - 08:00 AM ET

IDEV: To Present At Rodman & Renshaw Investment Conference @ 09:30 ET [delayed] - 11/10 - 07:53 AM ET

IDEV: To Present At Oppenheimer Healthcare Conference @ 08:40 ET [delayed] - 11/03 - 08:23 AM ET

Indevus initiates Phase III acromegaly trial - 10/01 - 09:42 AM ET

IDEV: Begins Ph III Trial of Octreotide Implant for Acromegaly - 09/30 - 08:24 AM ET

Indevus Announces Initiation of Phase III Clinical Trial of Octreotide Implant for Acromegaly - 09/30 - 08:00 AM ET

Indevus Pharmaceuticals Closes At Multi-Month High - 09/26 - 04:19 PM ET

Stockwire.com: Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) just released some important news. - 09/26 - 01:14 PM ET

UPDATE 1-Indevus shares soar on positive testosterone drug news - 09/26 - 01:00 PM ET

Indevus Pharmaceuticals Races Higher On FDA Resubmission Of NDA For NEBIDO - 09/26 - 09:59 AM ET

BRIEF-Indevus to re-submit New Drug Application for NEBIDO - 09/26 - 09:14 AM ET

IDEV: Agreement w/FDA re Additional Data for Resubmission of NEBIDO(R) NDA - 09/26 - 09:07 AM ET

Indevus and FDA Agree on Path Forward for NEBIDO(R) - 09/26 - 09:00 AM ET

IDEV: To Present At UBS Global Life Sciences Conference @ 14:30 ET [delayed] - 09/22 - 12:52 PM ET

Indevus Pharmaceuticals Scheduled to Present at 2008 UBS Global Life Sciences Conference - 09/16 - 08:00 AM ET

Indevus completes enrollment for Phase III study of HIV drug - 08/25 - 11:01 AM ET

IDEV: Completion of Enrollment for Ph III Trial of PRO 2000 - 08/22 - 08:03 AM ET

Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 - 08/22 - 08:00 AM ET

Page 1 of 6     1  2   3   4   5   >   >>|     Previous  |  Next

<< Back to Stock Index